ArticleCancer research2018
Loss of Pax5 Exploits Sca1-BCR-ABL
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 51 citations in OpenAlex.
- Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells.JCI insight · 2026Article
- PD-1 Expression Promotes Immune Evasion in B-ALL.Hematology reports · 2025Article
- The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025Review
- Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.Leukemia · 2025Article
- Cell Lineage Affiliation During Hematopoiesis.International journal of molecular sciences · 2025Review
- Childhood B cell leukemia: Intercepting the paths to progression.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway.Cell communication and signaling : CCS · 2024Article
- Article
- Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice.Nature communications · 2023Article
- Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia.Frontiers in immunology · 2023Review
- Childhood B-Cell Preleukemia Mouse Modeling.International journal of molecular sciences · 2022Review
- The Social Norm of Hematopoietic Stem Cells and Dysregulation in Leukemia.International journal of molecular sciences · 2022Review
- Oncogenes and the Origins of Leukemias.International journal of molecular sciences · 2022Review
- Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.Blood advances · 2022Article
- Comparison Study on Sonodirect and Sonoalternate Current Electrocoagulation Process for Domestic Wastewater Treatment.International journal of analytical chemistry · 2022Article
- Lessons to cancer from studies of leukemia and hematopoiesis.Frontiers in cell and developmental biology · 2022Review
- Review
- Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells.Cancers · 2021Review
- Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells.International journal of molecular sciences · 2021Review
- Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia.Nature reviews. Immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Alberto Martín-LorenzoExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
Franziska AuerDepartment of Systems Biology, Beckman Research Institute, Monrovia, California.
Lai N ChanDepartment of Systems Biology, Beckman Research Institute, Monrovia, California.
Idoia García-RamírezExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
Inés González-HerreroExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
Guillermo Rodríguez-HernándezExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
Christoph BartenhagenInstitute of Medical Informatics, University of Muenster, Muenster, Germany.
Martin DugasInstitute of Medical Informatics, University of Muenster, Muenster, Germany.
Michael GombertDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, Dusseldorf, Germany.
Sebastian GinzelDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf, Medical Faculty, Dusseldorf, Germany.
Oscar BlancoDepartamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.
Alberto OrfaoServicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
Diego Alonso-LópezBioinformatics Unit, Cancer Research Center (CSIC-USAL) Salamanca, Spain.
Javier De Las RivasInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Maria B García-CenadorDepartamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
Francisco J García-CriadoDepartamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
Markus MüschenDepartment of Systems Biology, Beckman Research Institute, Monrovia, California. Julia.Hauer@med.uni-duesseldorf.de muschen@coh.org Arndt.Borkhardt@med.uni-duesseldorf.de cvd@usal.es.
Isidro Sánchez-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.
Arndt BorkhardtInstitute of Medical Informatics, University of Muenster, Muenster, Germany. Julia.Hauer@med.uni-duesseldorf.de muschen@coh.org Arndt.Borkhardt@med.uni-duesseldorf.de cvd@usal.es.
Carolina Vicente-DueñasExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain. Julia.Hauer@med.uni-duesseldorf.de muschen@coh.org Arndt.Borkhardt@med.uni-duesseldorf.de cvd@usal.es.
Julia HauerInstitute of Medical Informatics, University of Muenster, Muenster, Germany. Julia.Hauer@med.uni-duesseldorf.de muschen@coh.org Arndt.Borkhardt@med.uni-duesseldorf.de cvd@usal.es.
Instituto de Investigación Biomédica de Salamanca · ES
Funding
Metabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MPRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAR01CA137060 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2016
$2.7MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MNegative feedback signaling in tyrosine kinase-driven leukemiaR01CA172558 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kTargeting BCL6 in tyrosine kinase-driven leukemiaR01CA169458 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kHoward Hughes Medical Institute HHMI-55108547NCI NIH HHS R01 CA137060NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA169458NCI NIH HHS R01 CA172558NCI NIH HHS R01 CA213138NCI NIH HHS R35 CA197628Wellcome Trust
Abstract
Preleukemic clones carrying
Indexed as
AnimalsB-LymphocytesCell LineEnergy MetabolismFusion Proteins, bcr-ablGene Expression Regulation, LeukemicGlucoseHEK293 CellsHumansMiceMice, Inbred C57BLMice, Inbred CBAMice, TransgenicPAX5 Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPreleukemiaFusion Proteins, bcr-ablGlucosePAX5 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.